Evidence map›Paper›PMID 36389795›Full record

ArticleFrontiers in immunology2022

Early treatment with anti-α

Samuel D Johnson, Lindsey A Knight, Narendra Kumar, Omalla A Olwenyi, Michellie Thurman, Smriti Mehra, Mahesh Mohan, Siddappa N Byrareddy

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Samuel D JohnsonDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States.
Lindsey A KnightDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Narendra KumarDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Omalla A OlwenyiDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States.
Michellie ThurmanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
Smriti MehraSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, United States.
Mahesh MohanSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, United States.
Siddappa N ByrareddyDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
University of Nebraska Medical Center · USTexas Biomedical Research Institute · US

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
Viral Testing CoreU42OD010442 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Deepak Kaushal, Kathryn Shelton · 2012 to 2026
$35.6M
Myeloid and lymphoid immunity-specific mechanisms of IDO mediated immunosuppression and its reversal, during TBR01AI134245 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI Smriti Mehra · 2018 to 2026
$6.2M
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection-supplementR01DA052845 · NIDA · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI BYRAREDDY, SIDDAPPA N, MOHAN, MAHESH · 2020 to 2024
$4.0M
Limiting HIV establishment and maintenace by preserving intestinal immunityR01AI129745 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BYRAREDDY, SIDDAPPA N, PAIARDINI, MIRKO · 2017 to 2020
$3.3M
Neuroimmunology of Disease Training ProgramT32NS105594 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aditya N Bade, Howard E Gendelman · 2018 to 2026
$1.4M
Targeting gut-brain axis to eliminate CNS reservoirsR21MH113455 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BYRAREDDY, SIDDAPPA N · 2017 to 2018
$414k
NIAID NIH HHS R01 AI129745NIAID NIH HHS R01 AI134245NIDA NIH HHS R01 DA052845NIH HHS P51 OD011133NIH HHS U42 OD010442NIMH NIH HHS R21 MH113455NINDS NIH HHS T32 NS105594
6 · The paper itself

Abstract

Despite advances in combination antiretroviral therapy (cART), people living with HIV (PLWH) continue to experience gastrointestinal dysfunction. Infusions of anti-α

Indexed as

HIV InfectionsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsAntibodiesMacaca mulattaMacrophagesAntibodiesbutyratemacrophage maturationmicrobiomemucosal immunologymyeloid cellssimian immunodeficiency virus (SIV)viral reservoirα4β7 integrin

Identifiers

PMID36389795
PMCPMC9664000
OpenAlexW4307756649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.